Elpiscience is a Shanghai, China and Germantown, MD-based clinical stage biopharmaceutical company focused on innovating and developing next-generation immunotherapy to benefit cancer patients worldwide. This morning Elpiscience announced that its first patient was does in the US Phase I clinical trial of Anti-CD39 monoclonal antibody ES002 for treatment of advanced solid tumors.
Earlier this month, Dr. John Craighead was announced as chief financial officer effective on Jan. 4th 2022. Craighead will lead all finance and corporate development functions for the company.
Additional information can be seen in the press release below:
GERMANTOWN, Md.–(BUSINESS WIRE)–Elpiscience Biopharmaceuticals, Inc. (“Elpiscience”), a global clinical-stage biopharmaceutical company dedicated to discovering and developing next-generation cancer immunotherapies, today announced that the first patient has been dosed in a U.S. multi-center, Phase I clinical trial, evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of ES002, the company’s proprietary anti-CD39 monoclonal antibody (mAb), that is being developed for the treatment of advanced solid tumors (NCT05075564). Elpiscience received U.S. Food and Drug Administration (FDA) IND clearance for ES002 in September 2021.
“We are very pleased to see ES002 enter clinical trial testing in the United States,” said Steve Chin, CMO of Elpiscience. “This is an important milestone for Elpiscience to develop innovative and differentiated cancer immunotherapies. We look forward to announcing additional clinical milestones throughout 2022 as Elpiscience expands its pipeline with a steadfast commitment to advance One World Class Molecule into the Clinic Each Year.”
ES002 has demonstrated highly potent single-agent anti-tumor activity showing significant reduction in tumor size and weight in in-vivo pharmacology studies.
ES002 is an anti-CD39 mAb designed to promote anti-tumor immunity. CD39 is a key enzyme regulating the production of adenosine, a critical immune suppressor. By blocking CD39 function, ES002 also stabilizes pro-inflammatory extracellular ATP (eATP) and restores anti-tumor immunity within the tumor microenvironment. ES002 demonstrated highly potent single-agent anti-tumor activity in in-vivo pharmacology studies.
Elpiscience is a clinical stage biopharmaceutical company focused on innovating and developing next-generation immunotherapy to benefit cancer patients worldwide. The company has a robust pipeline of globally innovative molecules, covering wide range of targets in immuno-oncology. It has four molecules in clinical trials (ES002, ES101, ES102, and ES104), and endeavors to clinically advance at least one innovative molecule a year. Founded and managed by a team of biopharma industry leaders, Elpiscience is backed by renowned investors including, Lilly Asia Ventures, Hillhouse Capital, Hyfinity Investments, Greater Bay Area Homeland Development Fund, CDH, DYEE Capital and Cormorant Asset Management.
Learn more at elpiscience.com
With good money management skills being crucial for financial success and a good credit score, the personal-finance website WalletHub today released its report on the Cities Where People Have the…
A Wind Advisory remains in effect on Wednesday, starting at 6pm until 4am Thursday.
Los Chorros Restaurant, located at 2420 Blueridge Ave., has been servicing the Wheaton area since 1989. This month the restaurant is celebrating its 35th anniversary.
MoCo High School Sports Playoff Scores for Feb 27, 2024:
AC Milan Academy is hosting a soccer camp at Maryland Soccerplex from March 1st through March 3rd for girls and boys aged 5 to 16 from any club who want to develop their soccer skills and learn the unique methodology of AC Milan directly from AC Milan coaches.
March 1st (Friday) 6pm-7:30pm
March 2nd (Saturday) 6pm-7:30pm
March 3rd (Sunday) 10:30am -12pm and 3:30pm-5pm
Location:18031 Central Park Cir, Boyds, MD 20841
Price: $349 + AC Milan Junior Camp Kit